The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.
Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.
Evidence-based treatments for androgenic alopecia, such as minoxidil, finasteride, low-level laser light therapy, dutasteride, platelet-rich plasma, and topical ketoconazole. It discusses the efficacy, safety, and mechanism of action of these treatments, as well as future developments in understanding this polygenic condition.
Hair loss discussion involves PRP (platelet rich plasma) treatment. PRP doesn't stop hair loss, only promotes regrowth; minoxidil is suggested as a better alternative.
A user who has tried multiple treatments for hair loss, including oral and topical finasteride and liposomal finasteride, but experienced severe side effects in each case; the user is considering trying RU58841 or aromatise inhibitors as alternatives.
A 39-year-old experienced hair regrowth on his temples after switching from finasteride to topical RU58841 combined with 5% minoxidil. He also underwent stem cell treatment and noticed improvements, attributing the regrowth mainly to the change in treatment.
The conversation discusses whether not masturbating (semen retention) affects hair loss, with opinions varying but generally dismissing the idea. Some participants mention using hair loss treatments like Minoxidil, Finasteride, and RU58841, but the effectiveness and relation to prolactin levels in the scalp are debated.
Topical spironolactone 5% is being discussed for its effectiveness in treating hair loss, specifically receding temples. The user is inquiring if it works similarly to finasteride as a testosterone blocker.
The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.
PRP treatment for hair loss shows some evidence of effectiveness, with HT surgeons using it post-op to promote growth. Microneedling is mentioned as a cheaper alternative.
Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.
OP is considering adding dutasteride to their regimen of finasteride and minoxidil to address hair loss plateauing. Users suggest oral minoxidil, microneedling, and possibly a hair transplant, with mixed opinions on dutasteride's effectiveness for temple regrowth.
Finasteride may affect liver function and cortisol levels, potentially linking it to non-alcoholic fatty liver disease (NAFLD). More research is needed to understand this connection fully.
The conversation discusses the effectiveness of pyrithione zinc and GT20029 for hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.
A user reports high DHT levels despite taking finasteride and is concerned about inconsistent blood test results. They also take modafinil, vitamin D, and magnesium supplements.
The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.
Pyrilutamide is being discussed as an alternative for those who can't use finasteride, but users report it may be ineffective at low concentrations. Some users are combining it with minoxidil, microneedling, and other treatments, but results vary.
The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.
Creatine does not significantly affect hair loss when taking finasteride. Some users report no change, while others believe it may accelerate hair loss if predisposed to male pattern baldness.
Kevin Mann avoids dutasteride because it comes in gelatin capsules, which he avoids as a vegan, and he is satisfied with finasteride's results. He prefers finasteride due to more long-term research and follows the principle of "if it ain't broke, don't fix it."
Verteporfin treatment shows promise for hair regeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.
A 35-year-old is considering Breezula, Pyrilutamide, or topical finasteride/dutasteride to protect against hair loss while on testosterone replacement therapy (TRT). They currently use finasteride, oral minoxidil, and dutasteride but experienced increased hair shedding with TRT.
Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.
Rapamycin, finasteride, and minoxidil are discussed as a strategy for hair loss prevention and reversal. Pulsed dosing of rapamycin is suggested to avoid conflicting effects with minoxidil.
Dutasteride can cause hair shedding even with suppressed testosterone levels due to previous damage from DHT. Hair shedding is often a sign of damaged hair being replaced by healthier growth.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.